Share on StockTwits

BioTime (NYSE:BTX) Director Broadwood Partners Lp bought 1,000,000 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $2,500,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of BioTime (NYSE:BTX) traded down 0.31% during mid-day trading on Wednesday, hitting $3.26. 210,842 shares of the company’s stock traded hands. BioTime has a 1-year low of $2.21 and a 1-year high of $4.31. The stock has a 50-day moving average of $2.66 and a 200-day moving average of $3.28. The company’s market cap is $192.6 million.

BioTime (NYSE:BTX) last released its earnings data on Monday, May 12th. The company reported ($0.14) EPS for the quarter. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $0.61 million.

BioTime, Inc is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (NYSE:BTX) cell lines, and royalties from Hextend.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.